Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 33

1.

Natural killer cell lymphoma in a pediatric patient with inflammatory bowel disease.

Deneau M, Wallentine J, Guthery S, O'Gorman M, Bohnsack J, Fluchel M, Bezzant J, Pohl JF.

Pediatrics. 2010 Oct;126(4):e977-81. doi: 10.1542/peds.2010-0486. Epub 2010 Sep 13.

PMID:
20837584
2.

Risks of serious infection or lymphoma with anti-tumor necrosis factor therapy for pediatric inflammatory bowel disease: a systematic review.

Dulai PS, Thompson KD, Blunt HB, Dubinsky MC, Siegel CA.

Clin Gastroenterol Hepatol. 2014 Sep;12(9):1443-51; quiz e88-9. doi: 10.1016/j.cgh.2014.01.021. Epub 2014 Jan 22. Review.

PMID:
24462626
3.

Primary central nervous system extranodal NK/T cell lymphoma, nasal type, with antecedent hemophagocytic syndrome in a child.

Jiang X, Yin W, Song J, Chen X, Zhao C, Wen F.

Pediatr Dev Pathol. 2014 Nov-Dec;17(6):482-6. doi: 10.2350/14-02-1441-CR.1. Epub 2014 Sep 10. Review.

PMID:
25207703
4.
5.

Safety of infliximab and other biologic agents in the inflammatory bowel diseases.

Reddy JG, Loftus EV Jr.

Gastroenterol Clin North Am. 2006 Dec;35(4):837-55. Review.

PMID:
17129816
6.

A decade of infliximab: The Austrian evidence based consensus on the safe use of infliximab in inflammatory bowel disease.

Miehsler W, Novacek G, Wenzl H, Vogelsang H, Knoflach P, Kaser A, Dejaco C, Petritsch W, Kapitan M, Maier H, Graninger W, Tilg H, Reinisch W; Austrian Society of Gastroenterology and Hepatology.

J Crohns Colitis. 2010 Sep;4(3):221-56. doi: 10.1016/j.crohns.2009.12.001. Epub 2010 Mar 17.

7.

Lymphoma and other lymphoproliferative disorders in inflammatory bowel disease: a review.

Subramaniam K, D'Rozario J, Pavli P.

J Gastroenterol Hepatol. 2013 Jan;28(1):24-30. doi: 10.1111/jgh.12015. Review.

PMID:
23094824
8.

Management of inflammatory bowel disease with infliximab and other anti-tumor necrosis factor alpha therapies.

Magro F, Portela F.

BioDrugs. 2010 Dec 14;24 Suppl 1:3-14. doi: 10.2165/11586290-000000000-00000. Review.

PMID:
21175228
9.

Safety of infliximab for the treatment of inflammatory bowel disease: current understanding of the potential for serious adverse events.

Khanna R, Feagan BG.

Expert Opin Drug Saf. 2015 Jun;14(6):987-97. doi: 10.1517/14740338.2015.1029915. Epub 2015 Mar 29. Review.

PMID:
25819509
10.

[Biologics in current therapy for inflammatory bowel disease].

Hisamatsu T, Hibi T.

Nihon Rinsho Meneki Gakkai Kaishi. 2009 Jun;32(3):168-79. Review. Japanese.

11.

Therapeutic potential of infliximab in inflammatory bowel disease.

Hurd LB, Lichtenstein GR.

Gastroenterol Nurs. 1999 Sep-Oct;22(5):199-208. Review.

PMID:
10776108
12.

Review article: Infliximab therapy for inflammatory bowel disease--seven years on.

Rutgeerts P, Van Assche G, Vermeire S.

Aliment Pharmacol Ther. 2006 Feb 15;23(4):451-63. Review.

13.

An update on biosimilar drugs for inflammatory bowel disease.

Schreiber S.

Expert Rev Gastroenterol Hepatol. 2015;9 Suppl 1:1-3. doi: 10.1586/17474124.2015.1091305. Review.

PMID:
26395529
14.

Epstein-Barr virus-associated T/natural killer-cell lymphoproliferative disorders.

Park S, Ko YH.

J Dermatol. 2014 Jan;41(1):29-39. doi: 10.1111/1346-8138.12322. Review.

PMID:
24438142
15.

Clinical use and mechanisms of infliximab treatment on inflammatory bowel disease: a recent update.

Guo Y, Lu N, Bai A.

Biomed Res Int. 2013;2013:581631. doi: 10.1155/2013/581631. Epub 2013 Jan 21. Review.

16.

A systematic review of factors that contribute to hepatosplenic T-cell lymphoma in patients with inflammatory bowel disease.

Kotlyar DS, Osterman MT, Diamond RH, Porter D, Blonski WC, Wasik M, Sampat S, Mendizabal M, Lin MV, Lichtenstein GR.

Clin Gastroenterol Hepatol. 2011 Jan;9(1):36-41.e1. doi: 10.1016/j.cgh.2010.09.016. Epub 2010 Oct 1. Review.

PMID:
20888436
17.

Hepatosplenic T-cell lymphoma and inflammatory bowel disease.

Thai A, Prindiville T.

J Crohns Colitis. 2010 Nov;4(5):511-22. doi: 10.1016/j.crohns.2010.05.006. Epub 2010 Jun 25. Review.

18.

Nonnasal lymphoma expressing the natural killer cell marker CD56: a clinicopathologic study of 49 cases of an uncommon aggressive neoplasm.

Chan JK, Sin VC, Wong KF, Ng CS, Tsang WY, Chan CH, Cheung MM, Lau WH.

Blood. 1997 Jun 15;89(12):4501-13. Review.

19.

The immunogenicity of biosimilar infliximab: can we extrapolate the data across indications?

Ben-Horin S, Heap GA, Ahmad T, Kim H, Kwon T, Chowers Y.

Expert Rev Gastroenterol Hepatol. 2015;9 Suppl 1:27-34. doi: 10.1586/17474124.2015.1091307. Review.

PMID:
26395532
20.

Anti-TNF therapy in inflammatory bowel diseases: a huge review.

Peyrin-Biroulet L.

Minerva Gastroenterol Dietol. 2010 Jun;56(2):233-43. Review.

PMID:
20485259

Supplemental Content

Support Center